CXCR4 blockade induces atherosclerosis by affecting neutrophil function by Bot, Ilze et al.
CXCR4 blockade induces atherosclerosis by affecting neutrophil 
function
Ilze Bota,*, Isabelle T.M.N. Daissormontb, Alma Zerneckec, Gijs H.M. van Puijveldea, Birgit 
Krampd, Saskia C.A. de Jagera, Judith C. Sluimerb, Marco Mancab, Veronica Hériasb, 
Marijke M. Westraa, Martine Bota, Peter J. van Santbrinka, Theo J.C. van Berkela, Lishan 
Sue, Mona Skjellandf, Lars Gullestadg, Johan Kuipera, Bente Halvorsenh, Paul Aukrusth, 
Rory R. Koenend, Christian Weberd, and Erik A.L. Biessena,b
aDivision of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, 
Leiden, The Netherlands bExperimental Vascular Pathology Group, Cardiovascular Research 
Institute Maastricht, University of Maastricht, Maastricht, The Netherlands cRudolf-Virchow-
Center/DFG-Research Center for Experimental Biomedicine, University of Würzburg, Würzburg, 
Germany dInstitute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München, 
Munich, Germany eDepartment of Microbiology & Immunology, Lineberger Comprehensive 
Cancer Center, Curriculum in Genetics and Molecular Biology School of Medicine, The University 
of North Carolina, Chapel Hill, NC 27599-7295 fDepartment of Neurology, Rikshospitalet 
University Hospital, University of Oslo, Norway gDepartment of Cardiology, Rikshospitalet 
University Hospital, University of Oslo, Norway hDepartment of Internal Medicine, Rikshospitalet 
University Hospital, University of Oslo, Norway
Abstract
Aims—The SDF-1α/CXCR4 dyad was previously shown by us and others to be instrumental in 
intimal hyperplasia as well as early stage atherosclerosis. We here sought to investigate its impact 
on clinically relevant stages of atherosclerosis in mouse and man.
Methods and results—Immunohistochemical analysis of CXCR4 expression in human 
atherosclerotic lesions revealed a progressive accumulation of CXCR4+ cells during plaque 
progression. To address causal involvement of CXCR4 in advanced stages of atherosclerosis we 
reconstituted LDLr−/− mice with autologous bone marrow infected with lentivirus encoding 
SDF-1α antagonist or CXCR4 degrakine, which effects proteasomal degradation of CXCR4. 
Functional CXCR4 blockade led to progressive plaque expansion with disease progression, while 
also promoting intraplaque haemorrhage. Moreover, CXCR4 knockdown was seen to augment 
endothelial adhesion of neutrophils. Concordant with this finding, inhibition of CXCR4 function 
increased adhesive capacity and reduced apoptosis of neutrophils and resulted in hyperactivation 
of circulating neutrophils. Compatible with a role of the neutrophil CXCR4 in end-stage 
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atherosclerosis, CXCR4 expression by circulating neutrophils was lowered in patients with acute 
cardiovascular syndromes.
Conclusion—In conclusion, CXCR4 contributes to later stages of plaque progression by 
perturbing neutrophil function.
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1. Introduction
Leukocyte recruitment to the plaque is a crucial step in the progression of atherosclerosis 
[1–3]. Chemokines are chemotactic cytokines involved in the recruitment of leukocytes to 
the plaque [4–6] and several members of the CC- and CXC-chemokine family and their 
receptors have been implicated in the progression of cardiovascular disease. One of these 
CXC chemokines, CXCL12 (SDF-1α), was demonstrated to be expressed by vascular 
smooth muscle cells (vSMCs), endothelial cells, and macrophages in atherosclerotic but not 
healthy arteries [7,9]. Although these findings may suggest a potential role in 
atherosclerosis, the exact role of the SDF-1α/CXCR4 axis in atherosclerosis has long been 
unclear. A number of reports pointed to a pro-atherosclerotic role for SDF-1α due to its 
participation in platelet activation and leukocyte chemotaxis [7–9], while blockade of the 
SDF-1α/CXCR4 axis was demonstrated to inhibit neointima formation [10]. Conversely, 
Damås and colleagues demonstrated reduced SDF-1α levels in patients with unstable angina 
pectoris, and a causal role in this disease was inferred from the anti-inflammatory and 
matrix-stabilizing effects of SDF-1α [8]. This notion was corroborated by recent study by us 
showing that systemic blockade of CXCR4 by the CXCR4 antagonist AMD3465 enhanced 
plaque initiation due to increased neutrophil recruitment [11].
In this study, we mapped the actual expression levels of SDF-1α and its receptor CXCR4 at 
different stages of human atherosclerosis. The observed differential expression of SDF-1α/
CXCR4 expression in human atherosclerosis led us to investigate effects of CXCR4 
blockade on plaque formation and progression in mice by a loss-of-function approach using 
lentivirus encoding SDF-1α antagonist P2G [12] (LV.SDF-1α(P2G)) or CXCR4 degrakine 
(LV.CXCR4deg), which effects proteasomal CXCR4 degradation [13]. Our human and 
experimental data support a role of the CXCR4 axis in advanced atherosclerosis, potentially 
by regulating neutrophil senescence, and neutrophils adhesive and functional capacity.
2. Materials and Methods
For the detailed Methods section, see Supplementary material online.
2.1. Human cohort studies
2.1.1. Plaque analysis—Carotid artery samples were obtained either from patients 
undergoing carotid endarterectomy (Academic Hospital Maastricht or Maasland Hospital, 
Sittard, The Netherlands) or from autopsies performed at Department of Pathology, 
Academic Hospital Maastricht (The Netherlands). Carotid plaque tissue was classified for 
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progression stage according to the criteria designed by Virmani and coworkers [14]. All 
human work was approved by the Ethical Committee of the University Hospital Sittard/
Maastricht and was performed in accordance with the “Code for Proper Secondary Use of 
Human Tissue”.
Two further transcriptomics studies have been interrogated to corroborate the results from 
this study: (1) advanced versus early plaques from the GSE28829 study, and (2) advanced 
stable versus unstable plaques from the human plaque transcriptomics study [15].
2.1.2. Blood leukocyte analysis—To measure CXCR4 protein expression on human 
circulating granulocytes, granulocytes were purified from freshly isolated blood specimen 
from a cohort of healthy controls (n = 13), carotid endarterectomy (CEA, n = 5) and unstable 
angina pectoris patients (UAP, n = 19) using Lymphoprep™ according to the manufacturer’s 
protocol. This human work was approved by the Ethical Committee of the University 
Hospital Oslo. Signed informed consent for participation in the study was obtained from all 
individuals. Granulocytes were lysed and CXCR4 protein expression was determined by 
western blot analysis using a CXCR4 specific antibody (Abcam, Cambridge, USA). 
Detailed methodology of these studies is provided in the Supplemental Method section.
2.2. Animals
All animal work was approved by the regulatory authority of Leiden and Maastricht 
University and performed in compliance with the Dutch government guidelines. Female 
LDLr−/− mice received a bone marrow transplantation with bone marrow cells infected with 
lentivirus (LV). Empty, LV.SDF-1α(P2G) or LV.CXCR4deg (m.o.i. = 15) [16]. After 6 
weeks of recovery, mice were placed on a Western type diet for another 6 (n = 8 per group) 
and 10 weeks (n = 8–11 per group). Mice were anaesthetized by subcutaneous injection of 
ketamine (60 mg/kg, Eurovet Animal Health, Bladel, the Netherlands), fentanyl citrate and 
fluanisone (1.26 mg/kg and 2 mg/kg respectively, Janssen Animal Health, Sauderton, UK).
2.3. Neutrophil differentiation in vitro
HL60 cells were differentiated into neutrophils by incubating them for 5–7 days in medium 
containing 2.5 μM Retinoic Acid (RA) either in the presence or absence of the CXCR4 
antagonist AMD3100 (500 ng/mL) [17,18]. To measure proliferation, the differentiated cells 
were incubated with [3H]thymidine (Amersham, Uppsala, Sweden). To measure cell 
survival, HL60 cells were stained with Annexin V and propidium iodide (Sigma-Aldrich); 
cell survival rate (defined by non-apoptotic, non-necrotic cells) was determined by flow 
cytometry analysis. To determine neutrophil myeloperoxidase activity in the presence or 
absence of CXCR4 antagonist AMD3100, cells were lysed in Triton X-100 (Fluka, 
Zwijndrecht, the Netherlands). Cell lysate was diluted with 10 mM citrate (pH 5) after 
which substrate (100 μg/mL TMB, 0.003% H2O2, 13 μg/mL recorsinol in 10 mM citrate 
(pH5)) was added. The reaction was stopped with 2 M H2SO4 and absorbance was read at 
450 nm. Total RNA was extracted, reverse transcribed using M-MuLV reverse transcriptase 
(RevertAid, MBI Fermentas, Leon-Roth, Germany) and gene expression (Table 1) was 
measured by qPCR as described previously [19].
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LDLr−/− mice fed a Western type diet received daily an intraperitoneal injection of 
AMD3100 (2 μg/mouse) or PBS. Neutrophil senescence was assessed by flow cytometry 
analysis (CD11b+Ly6GhighDHR123+) on blood leukocytes, after incubation at 37 °C with 1 
μM dihydrorhodamine 123 (DHR123) and subsequent stimulation for 30 min with 20 μg/ml 
phorbol myristate acetate (PMA) to allow generation of intracellular H2O2.
2.5. Statistical analysis
Data are expressed as mean ± SEM. A 2-tailed Student’s t-test was used to compare 
individual groups. To determine the significance of the relative mRNA expression levels, 
statistical analysis was performed on Ct values. Non-parametric data were analyzed using a 
Mann–Whitney U test. Microarray data were processed as described in the supplemental 
methods section, and presented significances were adjusted for multiple testing. Multiple 
groups were analyzed using ANOVA with a subsequent Newman–Keuls Multiple 
comparisons post test. Contingency data were analyzed by means of the Fisher’s exact test. 
Data were considered statistically significant when P < 0.05.
3. Results
3.1. Differential expression of CXCR4 during human and mouse atherosclerotic lesion 
progression
First we have mapped CXCR4 and SDF-1α expression in atherosclerotic human carotid 
artery tissue obtained by endarterectomy (advanced stable versus advanced unstable plaque 
study; cohort 1) or after autopsy (early versus advanced stable plaque study; cohort 1) (for 
definitions of plaque stage see methods and supplemental methods sections). For all 
microarray studies tissues were sectioned and used for histology or transcriptomic analysis. 
The progression stage of transcriptomics sections was considered early (intimal thickening, 
IT), advanced stable (thick fibrous cap atheroma, TfcA) or advanced unstable (thin capped 
fibroatheroma with intraplaque hemorrharge (IPH), cap break or dissection, or intra/
extramural thrombi) if both of the adjacent sections were graded as such according to the 
morphological criteria of Virmani and coworkers [14]. Microarray (Fig. 1A) showed that 
CXCR4 expression was progressively up-regulated throughout disease progression, being 
significantly higher in advanced stable versus early plaques and most pronounced in 
advanced unstable lesions. This pattern could be confirmed in independent validation 
cohorts (cohorts 2), representing microarray studies of advanced versus early stable plaques 
(GSE28829; autopsy material) and of advanced unstable versus advanced stable plaques 
(endarterectomy specimen [15]). Increased SDF-1α mRNA expression was shown in human 
advanced stable versus early atherosclerotic lesions, whereas SDF-1α expression was 
significantly reduced in advanced unstable versus advanced stable lesions (Fig. 1A). Of 
note, both SDF-1α and CXCR4 mRNA expression levels were increased in atherosclerotic 
plaques of LDLr−/− in mice as compared to a non-diseased artery (Supplemental Fig. 1). 
Next, SDF-1α and CXCR4 mRNA expression data were verified at protein level by 
immunohistochemistry. Both proteins could be detected in normal arteries (Fig. 1B). 
SDF-1α expression was primarily localized in intimal leukocytes and medial vSMCs, and its 
expression decreased during plaque progression (Figs. 1B and C). These findings were 
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confirmed by subsequent co-staining showing moderate expression of SDF-1α in plaque 
macrophages (Supplemental Fig. 2A), vSMC (Supplemental Fig. 2B) and CD3+ T cells 
(Supplemental Fig. 2C). CXCR4 protein expression in advanced lesions was higher than in 
early lesions. However ruptured lesions showed an altered CXCR4 expression pattern, with 
hotspots at sites of neovascularization, but a reduction in overall staining intensity, which 
contrasts with the observed increment in mRNA expression (Figs. 1B and C). Co-staining 
showed moderate expression of CXCR4 by foam cells (Supplemental Fig. 3A) and by 
vSMC (Supplemental Fig. 3B). CXCR4 was only expressed by a fraction of plaque 
macrophages and vSMC, and we hypothesize that its expression may be linked to the 
differentiation stage of these cell subsets. In addition, almost all CD3+ T cells in the plaque 
were seen to express CXCR4 (Supplemental Fig. 3C). Plaque neutrophils were also seen to 
express CXCR4 (Supplemental Fig. 3D). A mouse IgG2b isotype control did not show any 
staining (Fig. 1D).
3.2. Effective impairment of CXCR4 function by SDF-1α antagonist and CXCR4 degrakine 
lentivirus in mice
The progressively altered SDF-1α/CXCR4 expression in human atherosclerosis led us to 
investigate effects of CXCR4 blockade at different stages of plaque formation by a lentivirus 
loss-of-function approach. Lentiviruses were generated encoding CXCR4 degrakine 
(LV.CXCR4deg) or SDF-1α antagonist (LV.SDF1α(P2G)) under the CMV promotor. An 
empty lentivector (LV.Empty) was used as control. To establish functionality of the 
lentivector, basal and SDF-1α induced motility of FDCP-MixA4 cells in the absence or 
presence of LV.SDF-1α(P2G) was measured in a slope-well assay (Supplemental Fig. 4). 
SDF-1α induced cell migration was completely blocked upon LV.SDF-1α (P2G) or 
LV.CXCR4deg infection (multiplicity of infection, MOI: 15) (Fig. 2A), comparable to 
infection with a lentivirus containing a shRNA sequence targeting CXCR4 (shX4HM), 
while SDF-1α was able to induce LV.Empty infected cell migration. Neutrophils isolated 
from mice transplanted with either LV.Empty or LV.CXCR4deg infected bone marrow 
displayed similarly reduced migration in response to SDF-1α (Fig. 2B).
Next, we tested LV.CXCR4deg functionality in vivo by reconstituting irradiated LDLr−/− 
mice with LV.CXCR4deg infected bone marrow. The total number of circulating CXCR4+ 
neutrophils (defined as CD11b+Ly6Ghigh cells as illustrated in Supplemental Fig. 5) was 
significantly reduced compared to that in control mice (Fig. 2C). When normalized to total 
neutrophil numbers, the percentage of CXCR4+ neutrophils was reduced from 41% ± 5% in 
the LV.Empty mice to 17 %± 3% in the LV.CXCR4deg mice (P < 0.001). Furthermore, 
CXCR4 expression (mean fluorescence intensity, MFI) per neutrophil was reduced from 
43.4 ± 2.1 in LV.Empty to 34.9 ± 1.6 in LV.CXCR4deg mice (P < 0.01). CXCR4 expression 
on CD3+ T cells was reduced (−38%: 74.2 ± 12.8 in controls versus 45.5 ± 5.8 in 
LV.CXCR4deg mice), as well as on CD19+ B cells (−30%, MFI: 65.5 ± 9.0 versus 46.3 ± 
5.6) and F4/80+ cells (−30%, MFI: 55.9 ± 11.7 versus 31.8 ± 1.6) in LV.CXCR4deg bone 
marrow transplanted mice compared to LV.Empty controls at 16 weeks after bone marrow 
transplantation, demonstrating that LV.CXCR4deg is an efficient tool to reduce CXCR4 
protein levels on leukocytes.
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3.3. Hematopoietic CXCR4 deficiency aggravates atherosclerotic lesion progression and 
induces intraplaque hemorrhages in LDLr−/− mice
To address the role of CXCR4 blockade on atherosclerosis, we examined lesion 
development and progression in LDLr−/− mice reconstituted with LV.CXCR4deg and 
LV.SDF-1α(P2G) infected bone marrow and fed a Western type diet. For plaque initiation 
and progression, aortic root lesions were examined after 6 and 10 weeks of Western type 
diet feeding, respectively. CXCR4 blockade increased plaque progression in LV.CXCR4deg 
treated mice compared to control mice (10 weeks after Western type diet; Fig. 3A, left panel 
and Supplemental Figs. 6A,B). Lesion progression also tended to be increased in 
LV.SDF-1α (P2G) bone marrow reconstituted mice, however this did not reach significance 
(P = 0.06). Atherosclerotic lesion development was not notably affected in the plaque 
initiation study (6 weeks of Western type diet feeding, Fig. 3A, right panel and 
Supplemental Figs. 6A,B). Interestingly, more lesions (5/8) of LV.CXCR4deg chimeras in 
the plaque initiation study displayed intraplaque hemorrhages (IPH) compared to LV.Empty 
controls (1/8) (Fig. 3B), and the area of extravasated intraplaque erythrocytes was enlarged 
in LV.CXCR4deg lesions (Fig. 3C). Analysis of the iron content of advanced lesions 
showed somewhat increased Perl’s Iron staining from 0.12% ± 0.05% in the LV.Empty 
group to 1.1% ± 0.8% in the LV.CXCR4deg mice, which may be illustrative of previous 
hemorrhage. There was no difference in plaque collagen and vSMC content (data not 
shown), while plaque macrophage content was unaltered as well (Fig. 3D). In addition, 
plaque T cell content did not differ between groups (Supplemental Fig. 6C). While as 
expected B cells were completely absent within the lesions, in the adventitia a few scattered 
B cells could be detected (data not shown). During the experiments, no differences were 
noticed between treatment groups in total body weight, plasma total cholesterol levels and 
lipid distribution (Fig. 3E).
3.4. Neutrophils show increased plaque adherence in the absence of CXCR4
In mouse plaques, neutrophils were seen to accumulate during lesion progression 
(Supplemental Fig. 7). As the SDF-1/CXCR4 dyad is important for neutrophil homeostasis, 
we analyzed effects on neutrophils in our study. The total number of 
CD11b+Ly6GhighCD71− blood neutrophils remained unaffected in LV.CXCR4deg versus 
LV.Empty transplanted chimeras (Fig. 4A). The number of intraplaque neutrophils was 
somewhat increased in the plaque initiation study (32 ± 10 neutrophils versus 21 ± 6 in 
controls), while neutrophil numbers decreased during plaque progression in both groups 
(data not shown). Interestingly, neutrophil adhesion to the plaque was highly increased in 
the LV.CXCR4deg transplanted mice compared to LV.Empty control mice both at 6 and 10 
weeks of Western type diet feeding (Fig. 4B). Next, we addressed effects of CXCR4 
blockage on neutrophil adherence in vitro. HL60 cells were differentiated into neutrophils 
with retinoic acid (Fig. 4C) [17,18]. Flow cytometry analysis confirmed that retinoic acid 
induced neutrophil differentiation as demonstrated by increased 
CD11b+Ly6GhighCD71−neutrophil numbers (data not shown). The adhesive capacity of 
HL60 cells differentiated in the presence of AMD3100 and retinoic acid was increased 
compared to HL60 cells differentiated in the sole presence of retinoic acid (26 ± 2 versus 18 
± 2 cells/microscopic field, Fig. 4D). HL60 cell adherence to fibronectin coated wells was 
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increased by 55%, however that of HL60 cells differentiated in the presence of AMD3100 
was even 2-fold higher (202%) compared to uncoated wells. Adherence of differentiated 
HL60 cells to gelatin remained unaltered by AMD3100 treatment. The augmented adhesive 
capacity was associated with altered outside in signaling as witness the 3-fold increased 
relative focal adhesion kinase (FAK) mRNA expression in HL60 derived neutrophils 
differentiated in the presence of AMD3100 (Fig. 4E). To confirm these in vitro findings, we 
next isolated bone marrow neutrophils from LV.Empty and LV.CXCR4deg transplanted 
mice and tested them for adhesive capacity to matrix and endothelial cells. Similarly as 
when using differentiated HL60 myeloblasts, adhesion of LV.CXCR4deg neutrophils to 
fibronectin coated wells was significantly increased as compared to LV.Empty control 
neutrophils (Fig. 4F). Furthermore, relative FAK mRNA expression was increased almost 2-
fold from 1.0 ± 0.4 *10−4 in LV.Empty control neutrophils to 1.9 ± 0.6*10−4 in 
LV.CXCR4deg neutrophils. In addition, neutrophil adhesion from LV.SDF-1α(P2G) 
expressing neutrophils to murine endothelial cells (H5V cells) was significantly increased as 
compared to LV.Empty neutrophils, while also the adhesion of LV.CXCR4deg expressing 
neutrophils tended to be increased (Fig. 4G).
We thus hypothesize that in our in vivo model, as the percentage of circulating CXCR4+ 
neutrophils is reduced by over 70%, the neutrophils adhering to the plaque are 
predominantly CXCR4low or even negative. Taken together, these findings indicate that 
disruption of the CXCR4/SDF-1α axis affects neutrophil adhesion in vitro as well as in vivo.
3.5. Impaired in vivo homing of neutrophils in response to SDF-1α but not KC and 
thioglycollate in LV.CXCR4deg transplanted mice
The increased adherent plaque neutrophils in LV.CXCR4deg mice led us to investigate 
effects of CXCR4 blockade on neutrophil migration in vivo. Leukocyte recruitment towards 
the peritoneum was measured in LDLr−/− mice, transplanted with either bone marrow 
infected with LV.Empty or LV.CXCR4deg, in response to PBS (control), KC or SDF-1α. 
Peritoneal homing of CD11b+Ly6Ghigh neutrophils in response to KC, which induces 
CXCR2 dependent neutrophil chemotaxis, did not differ between LV.Empty and 
LV.CXCR4deg chimeras (Fig. 5A). In contrast, the neutrophil migratory response to 
SDF-1α was decreased in LV.CXCR4deg transplanted mice (Fig. 5B). Importantly, CXCR4 
blockade on leukocytes did not affect thioglycollate elicited peritoneal neutrophil 
recruitment in AMD3100 treated LDLr−/− mice (Fig. 5C), demonstrating that decreased 
CXCR4 expression on leukocytes per se does not affect neutrophil migration in vivo. 
Apparently, while SDF-1α induced neutrophil migration was impaired in LV.CXCR4 
transplanted chimeras, the general migratory capacity of neutrophils remained unaltered.
3.6. CXCR4 regulates neutrophil homeostasis
Focal adhesion kinase (FAK) expression is critical for cell survival. Therefore, we next 
studied the impact of CXCR4 dysfunction on neutrophil homeostasis. AMD3100 treatment 
throughout retinoic acid induced neutrophil differentiation was seen to inhibit the formation 
of Ly6GhighCXCR4+ and Ly6GhighCXCR2+ neutrophil subsets (Fig. 6A). Moreover, 
AMD3100 reduced HL60 cell proliferation during retinoic acid differentiation (Fig. 6B), 
while augmenting neutrophil myeloperoxidase (MPO) activity (Fig. 6C), illustrative of 
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enhanced neutrophil activation. Furthermore, AMD3100 treated HL60 cells at 7 days after 
start of retinoic acid induced neutrophil differentiation showed increased cell survival (Fig. 
6D). In line, expression of cell survival factor AKT was enhanced (Fig. 6E).
The CXCR4 blockade associated cell survival response could well have impacted neutrophil 
senescence in vivo. Upon ageing neutrophils upregulate CXCR4 expression which mediate 
re-entry into the bone marrow, where they undergo apoptosis in a TNF-related apoptosis-
inducing ligand (TRAIL) dependent manner [20]. To investigate whether defective CXCR4 
expression leads to neutrophil retention in circulation, LDLr−/− mice were placed on 
Western type diet for 3 weeks and treated with AMD3100. AMD3100 treated mice showed 
higher CD11b+Ly6Ghigh granulocyte counts in blood than control mice (Fig. 7A). Flow 
cytometry of blood granulocytes for DHR123 revealed elevated levels of intracellular 
hydrogen, reflective of augmented reactive oxygen species (ROS) production and 
senescence, in this subset in AMD3100 treated mice (Fig. 7B). Thus, CXCR4 dysfunction 
leads to an increase of neutrophil survival, senescence and activation, which may be 
accompanied by enhanced neutrophil adhesion to vascular endothelium, and in this way to 
aggravated atherosclerosis. Damås and coworkers have shown that coronary artery disease 
(CAD) patients have lowered plasma levels of SDF-1α [8]. In a final experiment we sought 
to investigate the relevance of our findings for human disease. Supportive of our animal 
experimental findings, CXCR4 protein expression on circulating neutrophils isolated from 
CEA as well as from UAP patients was significantly lowered than compared to neutrophils 
from healthy controls (Fig. 7C). When further analyzing human atherosclerotic lesions, we 
observed that plaque MPO+ neutrophil content is >10 fold increased in advanced as 
compared to early stages of atherosclerosis (IT) (Supplemental Fig. 8), with more abundant 
presence in the plaque shoulder and cap regions. MPO-CXCR4 double-staining furthermore 
revealed that a large number of MPO+ neutrophils are CXCR4+ (thus activated) in IT and 
TfcA, with a trend towards increased presence of CXCR4− MPO+ cells in plaques with 
intraplaque hemorrhage (47% ± 12% versus 36% ± 5% for TfcA, and 25% in early lesions).
4. Discussion
Previously we demonstrated that the SDF-1α/CXCR4 axis is instrumental in early stage 
atherosclerosis by controlling circulating neutrophil counts in mice [11]. In this study we 
have extended this notion, focusing on later, clinically relevant stages of plaque 
development in mice and man. We show that plaque SDF-1α/CXCR4 expression is 
progressively deregulated during disease progression. Moreover, CXCR4 blockade was seen 
to aggravate advanced plaque formation and stability as judged by an increased frequency of 
intraplaque hemorrhages. These adverse effects of CXCR4 blockade were accompanied by 
enhanced endothelial adhesion of neutrophils, possibly due to enhanced focal adhesion. Our 
studies point to CXCR4 controlled neutrophil survival, senescence, and subsequent 
hyperactivation as conceivable cause of CXCR4’s atheroprotective activity.
The actual contribution of neutrophils to human atherosclerotic lesion development and 
progression has long been elusive, due to their scarce presence in human plaques, amongst 
others. However, evidence is mounting that neutrophils play a role in atherosclerosis [21]. 
The present study identifies CXCR4 as a regulator of neutrophil function in advanced 
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atherosclerosis in mice, and suggests that this disease axis may hold for human 
atherosclerosis as well.
Our histological data largely confirm previous work by Abi-Younes et al. [7], showing 
strong expression of SDF-1α and to a lesser extent also CXCR4 by endothelium, vSMCs 
and macrophages in the atherosclerotic plaque but not in healthy vessels. Moreover, we 
extend these findings, demonstrating that normal arteries do express SDF-1α, and that 
advanced unstable plaques show decreased SDF-1α expression, congruent with their 
decreased vSMC content. In contrast, CXCR4 expression was increased in more advanced 
lesions. In particular plaque leukocytes displayed high CXCR4 expression, possibly in 
response to the prevailing hypoxia [22,23]. Moreover, as plasma levels of this chemokine 
were shown to be progressively reduced in patients with stable and even more so with more 
unstable angina pectoris [8], the plaque CXCR4+ leukocyte accumulation may partly result 
from an increased SDF-1α gradient between circulation and plaque.
To delineate the contribution of leukocyte-derived SDF-1α/CXCR4 to plaque development 
and progression, we generated lentivirus vectors encoding an SDF-1α antagonist [12] and 
CXCR4 degrakine, respectively [13]. LDLr−/− mice reconstituted with LV.CXCR4deg 
lentivirus transduced bone marrow indeed displayed partially reduced CXCR4 protein 
expression by leukocytes compared to LV.Empty mice. Early plaque development was not 
affected by the reduced hematopoietic CXCR4 expression, however we did observe an 
increase in intraplaque erythrocyte accumulation, which was described to be involved in 
plaque destabilization [24,25]. The latter was confirmed by increased hemosider-in 
deposition in advanced plaques in both the LV.SDF-1α(P2G) and the LV.CXCR4degrakine 
group. Interestingly, at this stage lesion progression was severely increased in mice in which 
SDF-1α/CXCR4 signaling was inhibited, which may be explained by the increased 
accumulation of intraplaque erythrocytes with subsequent cholesterol deposition [26]. 
Previously, inhibition of CXCR4 signaling in a wire injury model of restenosis was 
associated with a decrease in vascular progenitor cell recruitment [10], resulting in reduced 
intimal thickening. However, in advanced atherosclerosis, plaque vSMC were seen to 
exclusively originate from arterial vSMC, and not to be of hematopoietic origin [27]. 
Furthermore, in this atherosclerosis model, no effects on lesional smooth muscle cell content 
was observed, suggesting that the relative contribution of vascular progenitor cells to the 
development atherosclerotic lesions in this model is not significant.
Blockage of CXCR4 has been shown to result in increased neutrophil release from bone 
marrow into circulation [28,29]. In ApoE−/− mice, complete and chronic blockage of 
CXCR4 with AMD3465, a CXCR4 antagonist, has been shown to increase blood neutrophil 
numbers, resulting in an increased accumulation of neutrophils within the atherosclerotic 
vessel wall and subsequently promoting plaque progression [11]. Partial blockage of 
CXCR4 in LV.CXCR4deg transfected bone marrow chimeras failed to induce neutrophil 
release into circulation, possibly due to compensatory effects such as reduced neutrophil 
production. Despite the lack of neutrophilia, CXCR4 blockade did aggravate plaque 
progression, possibly due to the increased adhesion of circulating neutrophils to plaque 
endothelium. In addition, neutrophils with impaired CXCR4 function showed increased 
intracellular ROS accumulation. Activated neutrophils elaborate a range of enzymes such as 
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neutrophil elastase and cathepsin G, antibacterial proteins, myeloperoxidases and radicals, 
and chemokines and cytokines.
In addition to increased activity, neutrophils lacking functional CXCR4 expression showed 
increased cell survival, as witness the impaired apoptosis and increased expression of the 
cell survival factor Akt in vitro. These data suggest a role for neutrophil senescence in 
atherosclerosis, however this still needs to be confirmed in vivo. As neutrophils age, they 
upregulate the expression of CXCR4 and acquire the ability to migrate back to bone marrow 
where they undergo apoptosis [20,30]. However, our study indicates that if mature 
neutrophils fail to upregulate functional CXCR4 expression, they will be retained in 
circulation to migrate towards inflamed tissue, such as the atherosclerotic vessel wall, where 
they may further promote inflammation, possibly due to excessive activation. It is tempting 
to speculate that cardiovascular disease (CVD) patients have dysfunctional CXCR4 
expression which in turn will lead to increased neutrophil senescence in blood and thus 
increased to neutrophil adherence to and activity in lesions. Indeed, in this study, we 
observed reduced number of CXCR4+ neutrophils in unstable human atherosclerotic 
plaques. It should be noted however that impaired CXCR4 function as in advanced human 
and mouse atherosclerosis probably acts deleterious by impeding activated neutrophil 
regress into bone marrow, and not only at the level of the plaque itself. Altogether, our data 
coincide with previous findings showing delayed neutrophil apoptosis in patients with 
unstable angina [29,30]. Whether neutrophil ageing is a cause or consequence of enhanced 
activation is still unknown.
A few limitations of this study are worth mentioning in this regard. First, while recent 
studies in mouse models of atherosclerosis have given new impetus to the notion that 
neutrophils are instrumental in the pathophysiology of disease [11,20,31], the actual impact 
of neutrophils in human disease is still controversial. Partly due to issues of technical (most 
human neutrophil antibodies lack specificity), and of intrinsic nature (neutrophils are very 
short-lived), only few reports have documented the presence of neutrophils in human 
plaques. Mostly their presence was confined to vulnerable and ruptured lesions, not 
coincidentally episodes of fulminant inflammation. In that respect, although our human and 
mouse data seem to point towards an increase in CXCR4 dependent neutrophil senescence 
and neutrophil adhesion, in particular in later stages of disease progression, translation of 
these findings to human disease should be handled with caution and yet remains to be 
established.
In conclusion, we provide clear indications for perturbed vascular homeostasis of SDF-1α 
and CXCR4 at later stages of atherogenesis in humans. Furthermore, we show that blockade 
of the SDF-1α/CXCR4 axis on leukocytes induces atherosclerotic plaque progression in 
mice, a finding that may be associated with an increased adherence to plaque endothelium 
and increased activity of neutrophils with impaired CXCR4 function. In addition, CXCR4 
dysfunctional neutrophils also show increased cell survival, suggesting an important role for 
neutrophil senescence in atherosclerosis.
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Fig. 1. Analysis of CXCR4 and SDF-1α expression in atherosclerotic human carotid artery 
plaques
A, Microarray analyses of CXCR4 and SDF-1α mRNA expression in human 
atherosclerosis. Four two-armed plaque cohorts were analyzed for mRNA expression 
patterns: advanced versus early stable carotid artery plaque cohorts obtained at autopsy 
(advanced:early cohort 1; n = 9 and 8, resp), advanced versus early stable carotid artery 
plaque cohort from GSE28829 which served as validation cohort (early/advanced cohort 2); 
advanced unstable versus stable plaque cohort (n = 12 and 3, respectively, unstable:stable 
cohort 1); a second advanced unstable versus stable plaque cohort from the human plaque 
transcriptomics study [16] (n = 22 and 22, stable/unstable cohort 2), both obtained by 
endarterectomy surgery. Values represent relative CXCR4 expression intensity in the first 
versus the second tissue component; all expression values were false-discovery-rate (FDR) 
corrected (*P < 0.05, **P < 0.01) B, CXCR4 and SDF-1α protein expression in non-
diseased arteries and early lesions, as well as in advanced and ruptured plaques 
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(magnification: 100×). Histological classification is described in the supplemental methods 
(* = lumen, I = intima and # = media). C, CXCR4 and SDF-1α expression by intimal cells 
(magnification: 400×). D, Mouse isotype IgG2b control (magnification: 100×).
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Fig. 2. In vitro and in vivo analysis of functionality of lentiviral CXCR4 degrakine and SDF-1α 
antagonist
A, Quantification of migrated FDCP-MixA4 cells infected with LV.Empty, LV.SDF1-
α(P2G), LV.CXCR4deg or a shRNA targeting CXCR4 (shX4HM) without stimulation 
(black bars) or in response to SDF-1α (white bars) in a slope well assay. (*P < 0.05 and **P 
< 0.01 compared to LV.Empty control, ##P < 0.01 compared to LV.Empty + SDF-1α). B, 
Quantification of migrated neutrophils, that were isolated from either LV.Empty control 
transplanted mice, or LV.CXCR4deg chimeras in a transwell migration assay. LV.CXCR4 
deg expressing neutrophils migrated significantly less towards SDF-1α (**P < 0.01 
compared to LV.Empty + SDF-1α). C, Flow cytometry analysis of relative circulating 
CXCR4+ neutrophils in LV.CXCR4deg versus LV.Empty chimeras (***P < 0.005).
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Fig. 3. CXCR4 and SDF-1α lentiviral blockade deteriorates atherosclerotic plaque progression
LDLr−/− mice were transplanted with LV.empty, LV.CXCR4deg or LV.SDF1(P2G) bone 
marrow and placed on Western type diet for 6 (plaque initiation study, n = 8 per group) and 
10 weeks (plaque progression study, n = 8–11 per group). A, Oil-Red-O staining of the 
aortic root. Blockade of CXCR4 by LV.CXCR4deg aggravated lesion progression after 10 
weeks of diet feeding in LDLr−/− mice (**P < 0.01 compared to LV.Empty, left graph). 
Similarly, hematopoietic overexpression of the SDF-1α(P2G) antagonist tended to induce 
lesion progression after 10 weeks of diet feeding (P = 0.06 compared to LV.Empty, left 
graph). Right panel: representative lesions of each group (50× magnification). Initial plaque 
development as measured after 6 weeks of western-type diet feeding was not affected by 
CXCR4 blockade (P = 0.25 compared to LV.Empty, right graph). B, Intraplaque 
hemorrhage in a LV.CXCR4deg plaque indicated by the arrow (upper left: 50× 
magnification, lower right: 200× magnification). C, Increased intraplaque hemorrhage was 
observed as measured by the relative erythrocyte surface area in plaques of LV.CXCR4deg 
chimeras (*P < 0.01). Data are represented for the 6 weeks group. D, Plaque macrophage 
(MOMA-2) content, represented as the percentage of MOMA2+ cells per plaque area. Data 
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are represented for the 10 weeks group. E, Plasma cholesterol level distribution did not 
differ between the groups.
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Fig. 4. CXCR4 blockage induces neutrophil adhesion
A, Flow cytometry analysis of the percentage of Ly6GhighCD11b+(CD71−) neutrophils in 
blood from LV.Empty (n = 4) versus LV.CXCR4deg (n = 4) bone marrow transplanted 
mice. Data are represented for the 6 weeks group. B, Napthol CAE staining showing 
adhering neutrophils to the plaque endothelium (left panel, upper picture: 400× 
magnification, lower picture: 1000× magnification). Represented in the graphs are the 
number of adhering neutrophils per endothelial cell length in LV.Empty versus 
LV.CXCR4deg transplanted LDLr−/− bone marrow chimeras 6 and 10 weeks after Western 
type diet feeding (**P < 0.01 compared to LV.Empty). C, HL60 cells were treated with 
retinoic acid to induce neutrophil development. D, Adhesion of non-treated versus 
AMD3100 treated neutrophils in control, fibronectin (FN) and gelatin coated wells. *P < 
0.05 compared to HL60 + RA, ##P < 0.01 compared to uncoated controls, **P < 0.01 
compared to HL60 + RA (FN). E, Relative gene expression of FAK in neutrophils 
differentiated in the presence or absence of AMD3100 (*P < 0.05). F, Adhesion of 
neutrophils isolated from bone marrow of LV.Empty versus LV.CXCR4deg transplanted 
mice to either control, fibronectin (FN) and gelatin coated wells. **P < 0.05 compared to 
LV.control, ###P < 0.001 compared to uncoated controls. G, Adhesion of neutrophils 
isolated from bone marrow of LV.Empty, LV.SDF-1α(P2G), LV.CXCR4deg transplanted 
mice to mouse endothelial cells. *P < 0.05 compared to LV.Empty control.
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Fig. 5. CXCR4 blockage does not alter neutrophil recruitment
In vivo chemokinesis assay in LDLr−/− mice, transplanted with either bone marrow infected 
with LV.Empty or LV.CXCR4deg A, Percentage of peritoneal Ly6GhighCD11b+(CD71−) 
neutrophils at 2 h after KC injection. ***P < 0.001 compared to T = 0. B, Percentage of 
recruited neutrophils in response to SDF-1α. *P < 0.05 compared to T = 0, #P < 0.05 
compared to LV.Empty. C, Percentage of peritoneal neutrophils in response to 3% Brewer’s 
Thioglycollate in control versus AMD3100 treated mice.
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Fig. 6. Neutrophils lacking functional CXCR4 expression show increased cell survival
A, Treatment of HL60 cells with AMD3100 inhibits differentiation of HL60 cells into 
neutrophils as demonstrated by a reduction in the percentage of Ly6GhighCXCR4+ (left 
panel) and Ly6GhighCXCR4+ cells (right panel) (**P < 0.01 compared to control HL60 
cells, ##P < 0.01 compared to RA differentiated HL60 cells). B, AMD3100 reduced 
neutrophil precursor proliferation during differentiation (**P < 0.01). C, Myeloperoxidase 
activity (**P < 0.01). D, Percentage of cell survival (***P < 0.001). E, Relative gene 
expression of Akt in neutrophils differentiated in the presence or absence of AMD3100 (*P 
< 0.05).
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Fig. 7. Increased numbers of senescent neutrophils in the absence of CXCR4
LDLr−/− mice on western type diet were treated with AMD3100 for 3 weeks. Control mice 
received PBS injections. A, Circulating Ly6GhighCD11b+ granulocyte numbers (*P < 0.05). 
B, Mean fluorescence intensity for DHR123 (*P = 0.05). C, Normalized CXCR4 protein 
expression on circulating granulocytes isolated from healthy (control) persons versus carotid 
endarterectomy (CEA) and patients with unstable angina pectoris (UAP, defined in the 
online methods) (**P < 0.01, ***P < 0.001 compared to controls).
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Table 1
Primer sequences used for RT-PCR analysis (m = murine, h = human).
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